drugset / Trial / NCT00267189

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

NCT00267189

Phase 3 Completed 145 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the effect of everolimus initiation together with reduction or discontinuation of calcineurin inhibitor (CNI) on renal function in maintenance liver transplant recipients with CNI-related renal impairment, while maintaining efficacy.

Timeline

Start
2005-11
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide
Comparator Everolimus Small molecule 1.5 mg
Subject Tacrolimus Small molecule
Background Azathioprine Small molecule
Background Mycophenolate acid Unknown

Indications

No indication recorded.